International HTA Agencies Collaborate On How To Determine Value-Based Prices
Health technology assessment agencies in the US, the UK and Canada are working together to develop new ways of determining value-based prices for potentially curative treatments like gene therapies.
You may also be interested in...
Canada has launched a new initiative under which drug sponsors will be able to request parallel scientific advice for regulatory and health technology assessment purposes.
Meindert Boysen, head of NICE’s Centre For Health Technology Evaluation, shares advice for companies aiming to get their medicine to patients. His golden rules: engage in early advice and be more realistic about pricing.
Softening provisions to make EU-wide joint clinical assessments voluntary would make proposed legislation on HTA cooperation redundant, says Eurordis.